key: cord-0695371-zztabjio authors: Pinnetti, C.; Vergori, A.; Agrati, C.; Castilletti, C.; Campioni, P.; Gagliardini, R.; Mondi, A.; Notari, S.; Amendola, A.; Cicalini, S.; Baldini, F.; Capobianchi, M.R.; Antinori, A. title: SARS-CoV-2 infection does not induce HIV viral escape in Central Nervous System: a case series date: 2020-09-17 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.09.040 sha: 25335ce5358c7a0de9492f04e1f352f9f82bffee doc_id: 695371 cord_uid: zztabjio We report two cases of HIV positive patients with COVID-19 infection and a recent diagnosis of opportunistic infections of central nervous system (CNS). We investigated the potential impact of coinfection with SARS-CoV-2 on HIV replication in CNS. We report two cases of HIV positive patients with COVID-19 infection and a recent diagnosis of opportunistic infections of central nervous system (CNS). We investigated the potential impact of coinfection with SARS-CoV-2 on HIV replication in CNS. Keywords: COVID-19; HIV infection; central nervous system; HIV viral escape. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of a clinical syndrome, coronavirus disease 2019 (COVID- 19) , associated with mild respiratory tract infections and severe pneumonia [1] . However, SARS-CoV-2 has been shown to affect other organs both directly, by binding to specific cellular receptors, and indirectly due to the triggered abnormal inflammatory response [2, 3] . Central nervous system (CNS) involvement has been reported and neurological signs and symptoms described [4, 5] . It is yet unclear whether persons living with HIV (PLWH) and on antiretroviral treatment, with low CD4 T-cell count (<200/mm 3 ), may have a higher risk of contracting COVID-19 and developing more serious clinical pictures of the disease [6] . HIV can itself affect neuronal compartment and the interaction on with CNS between the two viruses remains unexplored. 55-year-old ethiopian, suffering from hypertension and aortic steno-valvular insufficiency, on January 2020 has been diagnosed with HIV (CDC stage C), during the hospitalization for a meningitis caused by Mycobacterium chimera. A specific treatment with moxifloxacin/rifabutin/azitromycin/ethambutol was started and subsequently combined antiretroviral therapy (cART) with tenofovir disoproxil fumarate/emtricitabine and dolutegravir prescribed. After two months, while the patient was in a rehabilitation facility, a CSF examination revealed no pathological findings; all the microbiological tests on CSF were reported as negative. On 20 th April J o u r n a l P r e -p r o o f 3 2020, RT-PCR for SARS-CoV-2 on two nasal-pharyngeal swabs (NPSs) was also performed because contact of a COVID-19 case, in absence of symptoms, resulting positive. For this reason he was admitted to our COVID-Hospital. The patient was in fair clinical conditions, afebrile and eupnoic. The neurological examination showed hyposthenia of the lower limbs. HIV-RNA was <30 copies/ml in plasma and CD4-T cells count was 127/mm 3 (18%). A chest high resolution computed tomography (HRTC) revealed interstitial pneumonia and hydroxychloroquine therapy was administered for ten days, according to local guidelines, together with his previous therapy and antithrombotic prophylaxis. A MRI of the brain was performed for re-evaluation of his disease status (Figure 1a ,b). A lumbar puncture (LP) was performed and CSF examination showed an overlapping picture with the previous one. CSF and plasma albumin were 259 mg/L and 3390 mg/dl, respectively, with Link-index 0.47. The inflammatory profile on CSF showed low level of IL1β (0.17 pg/ml), IL-6 (8.65 pg/ml), IL-8 (36.17 pg/ml) and TNF-α (1.30 pg/ml). All microbiological tests resulted negative. RT-PCR for SARS-CoV-2 on CSF was negative and HIV-RNA on CSF/plasma pairs were undetectable/<30 cps/ml. Serology for SARS-CoV-2, performed using indirect immunofluorescence assay (IFA), was negative on CSF, while on plasma we found IgG title at 1:320, IgA 1:80 and a weak reactivity for IgM. The patient was discharged with three consecutive NPSs negative for SARS-CoV-2 and with the indication to continue anti-mycobacterial therapy and cART. and IgG 1:40. HIV-RNA was <30 copies/ml and CD4-T cell count 265/mm 3 (8.2%). A MRI of the brain was performed (Figure 1c,d) . A LP was performed and CSF examination showed only protein as 69.8 mg/dL. CSF and plasma albumin were 425 mg/L and 3640 mg/dl, respectively, with Link-index 0.5. The inflammatory profile in CSF showed IL1β (0.21 pg/ml), IL-6 (44.27 pg/ml), IL-8 (295.75 pg/ml) and TNF-α (8.70 pg/ml). All microbiological tests resulted negative, cryptococcal antigen was 1:8 on CSF and 1:400 on plasma. RT-PCR for SARS-CoV-2 on CSF was negative and HIV-RNA on CSF/plasma pairs were undetectable/<30 copies/ml. Serology for SARS-CoV-2 detected in CSF showed negative titles of IgA, IgM, while IgG were 1:8. During the hospital stay, consolidation therapy with fluconazole and cART were administered. No therapies for SARS-CoV-2 were prescribed, with the exception for antithrombotic prophylaxis. The patient was discharged after ten days. HIV viral escape is reported in a variable percentage of cases among cohorts of PLWH and especially specifically, a secondary HIV viral escape, due to CNS opportunistic diseases, has been observed in clinical reports [7] . The mechanisms of HIV neuro-invasion are still debated, it has been associated with Blood Brain Barrier (BBB) damage resulting from an immuneactivation or infected cells traffiking in the CNS [8] . SARS-CoV-2 might be neurotropic, indeed, a related necrotizing hemorrhagic encephalopathy has been described and an association with a marked inflammatory response hypotesized [9] . Neurological involvement in COVID-19 may mimick a heterogeneous spectrum of signs and symptoms and, in some cases, overlapping with other neurological diseases, including ischemic stroke, alterations of the consciousness state (confusion, sleepy state, seizure), muscle damage, acroparesthesias and symptoms of encephalitis [10] . Moreover, few data are available on prevalence and timing of COVID-19 neurologic symptoms, which often occurred delayed and in severe disease [11] . It has been hypothesized that SARS-CoV-2 could reach the CNS through several mechanisms: transynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium or leukocytes migration across the BBB [12] . There are data showing that SARS-CoV-2 infects lymphocytes, granulocytes and monocytes by binding to ACE-2 receptor [13] . In addition, cytokine storm, triggered by SARS-CoV-2, might be associated with an increased permeability of the BBB [12] . The potential role of the BBB in containing and preventing access to brain tissue could be crucial in patients with HIV co-infection, even if other concomitant CNS opportunistic pathologies, able to alter the BBB permeability, are present. We described a SARS-CoV-2 infection during a follow up for CNS pathologies and we supposed that SARS-CoV-2 could have altered the BBB permeability and caused a HIV escape in the CNS, with a potential consequent neuronal damage. However, this hypothesis has not been confirmed by virological and immunological tests performed on CSF. Indeed, we did not detect either SARS-CoV-2 RNA or HIV-RNA in the CSF. In one of the two cases we found the presence of IgG in the CSF, showing a passage across the BBB of these antibodies into the CSF. The absence of HIV in the CNS could be explained by the fact that both patients were correctly taking the specific therapy for the opportunistic infections as well as the cART. Moreover, the few symptoms associated with COVID-19 could suggest a contained inflammatory response in CNS/plasma, probably due to a low reactive immune response. Indeed these patients had a poor immunological recovery might contribute to avoid immune-pathogenetic processes and mitigate the symptoms [14] . A CNS study should be proposed to patients with SARS-CoV-2 and HIV co-infection, in order to clarify the interaction between HIV and SARS-CoV-2 and the associated inflammatory response and to optimize any ongoing treatments. Characteristics of and Important Lessons From the Coronavirus Disease Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19) The pathogenesis and treatment of the 'cytokine storm' in COVID-19 Neuroinvasion by human respiratory coronaviruses Neurologic features in severe SARS-CoV-2 infection A Survey for COVID-19 among HIV/AIDS Patients in Two Districts of Wuhan, China Highlights of the global HIV-1 CSF escape consortium meeting Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection: Neurologists Move to the Frontlines Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion The trinity of COVID-19: immunity, inflammation and intervention Figure 1 Legend a, b) CE-T1 SPGR3D axial scan shows subtle pachymeningeal enhancement in the bilateral frontotemporal region (patient 1) c,d) In the CE-T1 SPGR3D axial scan: enhancement of the meningeal plane on the posterior frontal left We gratfylly gratefully acknowledge medical and nursing staff of HIV/AIDS Clinical Unit and the two patients for their availability. We gratefully acknowledge the Collaborators Members of INMI COVID-19 study group.